Treace Medical Concepts, Inc.
NASDAQ:TMCIMedical - Devices
+$0.08 today
- Market cap
- $296.98M
- Beta
- 1.41
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.95
Volume 0.18M
Average 0.73M
TMCI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Treace Medical Concepts, Inc.NASDAQ: TMCI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $4.62M fell 16.9% year over year, behind the -7.4% change in trailing-twelve-month research & development. Sequentially, it rose 1.8% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.
Context
- Research & development amounted to 9.5% of revenue in FY2025, down 0.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -16.9% toward the trailing-twelve-month pace of -7.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 20.28M USD
- Year-over-year change
- -1.5%
- 4-year CAGR
- +18.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.28M | -1.5% |
| FY2024 | 2024-12-31 | 20.59M | +33.3% |
| FY2023 | 2023-12-31 | 15.44M | +13.7% |
| FY2022 | 2022-12-31 | 13.58M | +33.1% |
| FY2021 | 2021-12-31 | 10.2M | — |
Research & Development vs competitors
How TMCI compares with its peers on the latest reported figures
- TMCI's LTM Mar 2026 research & development of $19.34M is the 4th highest of the 8 companies compared; the peer median is $11.57M.
- Its year-over-year change of -7.4% is the 4th highest of 7, against a peer median of -5.5%.
- Research & development amounts to 9.3% of revenue for TMCI, versus a peer median of 3.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $37.65M | +2.6% | +14.1% | 29.5% | |
| LTM Mar 2026 | $22.48M | -43.6% | -11.4% | 26.1% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $21.06M | +43.4% | +38.3% | 22.2% |
| LTM Mar 2026 | $19.34M | -7.4% | +14.3% | 9.3% | |
| LTM Mar 2026 | $11.57M | -19.0% | -20.2% | 2.0% | |
| LTM Mar 2026 | $9.6M | +3.2% | +12.4% | 3.2% | |
| LTM Mar 2026 | $8.98M | -13.5% | +2.5% | 3.7% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TMCI) | $11.57M | -5.5% | +7.5% | 3.7% | |
Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 94.42M | 141.84M | 187.12M | 209.36M | 212.69M |
| Cost of Revenue | 16.89M | 27.52M | 35.18M | 41.09M | 42.94M |
| Gross Profit | 77.53M | 114.32M | 151.94M | 168.26M | 169.75M |
| Gross Margin | 82.1% | 80.6% | 81.2% | 80.4% | 79.8% |
| Research & Development | 10.2M | 13.58M | 15.44M | 20.59M | 20.28M |
| Selling, General & Admin | 83.84M | 137.57M | 187.93M | 203.36M | 203.62M |
| Operating Expenses | 94.04M | 149.16M | 203.37M | 223.95M | 223.91M |
| Depreciation & Amortization | 685K | 2.13M | 5.35M | 8.42M | 10.5M |
| EBITDA | (15.81M) | (36.28M) | (39.01M) | (42.07M) | (43.18M) |
| EBITDA Margin | -16.7% | -25.6% | -20.8% | -20.1% | -20.3% |
| Operating Income | (16.51M) | (34.84M) | (51.43M) | (55.69M) | (54.15M) |
| Operating Margin | -17.5% | -24.6% | -27.5% | -26.6% | -25.5% |
| Interest Income | 18K | 1.31M | 6.73M | 4.88M | 2.78M |
| Interest Expense | 4.06M | 4.4M | 5.17M | 5.26M | 5.32M |
| Other Income / Expenses | (4.04M) | (7.97M) | 1.9M | (55K) | (4.85M) |
| Income Before Tax | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Pre-Tax Margin | -21.8% | -30.2% | -26.5% | -26.6% | -27.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Net Margin | -21.8% | -30.2% | -26.5% | -26.6% | -27.7% |
| EPS (Basic) | (0.38) | (0.77) | (0.81) | (0.90) | (0.93) |
| EPS (Diluted) | (0.38) | (0.77) | (0.81) | (0.90) | (0.93) |
| Weighted Avg Shares | 54.18M | 55.28M | 60.85M | 62.11M | 63.27M |
| Weighted Avg Shares (Diluted) | 54.18M | 55.28M | 60.85M | 62.11M | 63.27M |
Treace Medical Concepts, Inc.
NASDAQ:TMCI
Intrinsic Alpha fair value
Locked
Current Price
$4.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.